{"id":576086,"date":"2023-07-07T00:00:00","date_gmt":"2023-07-07T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0009-2023-biopharma-parkinsons-disease-current-treatment-physician-insights-us-2023\/"},"modified":"2026-03-31T10:32:34","modified_gmt":"2026-03-31T10:32:34","slug":"cutrcg0009-2023-biopharma-parkinsons-disease-current-treatment-physician-insights-us-2023","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrcg0009-2023-biopharma-parkinsons-disease-current-treatment-physician-insights-us-2023\/","title":{"rendered":"Parkinson&#8217;s Disease | Current Treatment: Physician Insights | US | 2023"},"content":{"rendered":"<p>The treatment of Parkinson\u2019s disease (PD) requires personalized care, a high degree of polypharmacy, and frequent adjustments to achieve symptom control throughout the disease course. Consequently, treatment paradigms in PD have become increasingly complex as the growing availability and uptake of new brands have bolstered disease management with an array of mechanistically distinct drug classes. In addition to the SOC levodopa and generically available mainstays in entrenched drug classes, physicians prescribe branded agents that target niche PD subpopulations with high unmet need (e.g., Sunovion\u2019s Kynmobi, Supernus\u2019s Gocovri, Acadia\u2019s Nuplazid). With the PD therapy market poised to grow meaningfully\u2014thanks to a dynamic pipeline of unique therapies designed to optimize and lengthen the benefits of levodopa, reduce the severity of levodopa-induced dyskinesia, and reduce the frequency and impact of motor response complications\u2014understanding neurologists\u2019 prescribing practices and decision points when treating PD is crucial for developers facing a competitive and evolving market.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul>\n<li>What percentage of PD patients suffer from motor response complications and nonmotor comorbidities? What treatments do neurologists favor for these subpopulations?<\/li>\n<li>What percentage of PD patients suffering from levodopa-induced dyskinesia receive drug therapy and with which drugs?<\/li>\n<li>How frequently are branded agents from drug classes with generically available options prescribed for PD?<\/li>\n<li>How and why has neurologists\u2019 prescribing changed in the past year?<\/li>\n<li>What factors influence neurologists\u2019 treatment practices for their PD patients at each stage of disease?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n<p><strong>Markets covered:<\/strong> United States<\/p>\n<p><strong>Key companies: <\/strong>AbbVie, Acadia, Acorda, Amneal, Kyowa Kirin, Lundbeck, Neurocrine, Sunovion, Supernus<\/p>\n<p><strong>Key drugs:<\/strong> Duopa, Gocovri, Inbrija, Kynmobi, Neupro, Northera, Nourianz, Nuplazid, Ongentys, Rytary, Xadago, all generic mainstays<\/p>\n<p><strong>Primary research: <\/strong>Survey of 101 U.S. neurologists<\/p>\n<p><strong>Key insights provided<\/strong><\/p>\n<ul>\n<li>Factors influencing disease management and treatment decisions<\/li>\n<li>Drivers and constraints of treatment selection<\/li>\n<li>Physician-reported treatment practices and brand-level patient shares<\/li>\n<li>Rationale for changes in treatment approach<\/li>\n<li>Physician insight on persistency and compliance<\/li>\n<li>Physician-reported recent\u00a0\/ anticipated changes in brand usage or\u00a0treatment approach<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-576086","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-parkinsons-disease","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576086","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576086\/revisions"}],"predecessor-version":[{"id":577534,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/576086\/revisions\/577534"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=576086"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}